The first step of the study in liquid biopsy consisted of determining the plasma levels of sPD1 and sPD-L1 in a cohort of MM patients who subsequently underwent immunotherapy with anti-PD1. This evidence concerns the gene HOXD13 and Miyoshi myopathy.